Welcome to our dedicated page for Nextcure SEC filings (Ticker: NXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NextCure, Inc. (NASDAQ: NXTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on targeted therapies, including antibody-drug conjugates for cancer, NextCure uses its SEC filings to report material agreements, financing transactions, corporate actions and financial results.
Through Forms 8-K, NextCure reports events such as private placements of common stock and pre-funded warrants, reverse stock split approvals and implementation, strategic collaborations, executive changes and Annual Meeting voting results. For example, the company has filed 8-Ks describing a securities purchase agreement for a private placement that raised approximately $21.5 million in gross proceeds, the effectuation of a one-for-twelve reverse stock split, and the outcome of stockholder votes on director elections and other proposals.
Periodic reports such as 10-K annual reports and 10-Q quarterly reports (not reproduced here but referenced in the company’s press releases) typically include detailed discussions of NextCure’s pipeline, risk factors, research and development expenses, general and administrative costs and net losses. The company’s forward-looking statement and risk disclosures reference its limited operating history, lack of approved products, need for additional financing and clinical development uncertainties.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key terms, highlight important sections and help interpret complex legal and financial language. Real-time updates from EDGAR ensure that new NextCure filings appear promptly, including current reports on material events, equity issuances and corporate governance matters.
Investors can also use this page to track information relevant to capital structure and shareholder rights, such as reverse stock split details, amendments to the certificate of incorporation and unregistered sales of equity securities. Together, these filings offer a structured view of how NextCure manages its clinical-stage operations, finances its programs and complies with public company reporting requirements.
NextCure, Inc. reported that its Chief Operating Officer, Timothy Mayer, received an award of employee stock options. The grant covers 14,670 options with an exercise price of $10.85 per share and was dated January 30, 2026.
One fourth of the option grant vests on January 30, 2027, with the remaining options vesting in 36 monthly installments beginning February 28, 2027. Mayer holds all 14,670 derivative securities directly following this award.
NextCure, Inc. reported that President and CEO Michael Richman received a grant of 38,190 employee stock options on January 30, 2026. These options have an exercise price of $10.85 per share and expire on January 29, 2036.
According to the vesting schedule, one fourth of the option grant vests on January 30, 2027, with the remaining options vesting in 36 equal monthly installments beginning on February 28, 2027. Following this grant, Richman beneficially owns 38,190 derivative securities directly.
NextCure, Inc. insider filing shows a new stock option grant to its Chief Financial Officer, Steven P. Cobourn. On January 30, 2026, he received an employee stock option to buy 14,670 shares of NextCure common stock at an exercise price of $10.85 per share.
According to the vesting schedule, one fourth of the option vests on January 30, 2027, with the remaining three fourths vesting in 36 equal monthly installments starting February 28, 2027. This type of award is a standard form of equity compensation that links executive pay to the company’s future stock performance.
Affinity Asset Advisors, LLC and Michael Cho report a 9.99% beneficial stake in NextCure, Inc. common stock. They disclose beneficial ownership of 348,607 shares of Common Stock, based on 3,489,563 shares outstanding as of October 31, 2025.
The position includes 101,313 shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership limitation that caps how many shares can be acquired through exercise. The securities are held through Affinity Healthcare Fund, LP, for which Affinity Asset Advisors serves as investment manager and over which it exercises voting and investment power.
The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of NextCure. Both reporting persons certify the accuracy and completeness of the ownership information as of late January 2026.
NextCure, Inc. filed a current report describing its preliminary year-end liquidity and program updates. The company announced that as of December 31, 2025, it had approximately $41.8 million in cash, cash equivalents and marketable securities, and it currently expects these resources to fund planned operating expenses and capital expenditures into the first half of 2027. This cash figure is unaudited, subject to adjustment, and will be finalized with the company’s consolidated financial statements for 2025.
NextCure also filed a press release and an updated corporate presentation as exhibits, which include updates on its two antibody drug conjugate programs. The report highlights that certain statements, including those about cash runway, development plans, clinical progress and upcoming milestones, are forward-looking and subject to significant risks and uncertainties outlined in the company’s recent annual and quarterly reports.
NextCure, Inc. is registering 2,523,477 shares of common stock for resale by selling stockholders under a shelf prospectus. The shares consist of 708,428 outstanding shares and 1,815,049 shares issuable upon exercise of pre-funded warrants issued in a November 12, 2025 private placement.
Investors in that private placement bought common stock at $8.52 per share and pre-funded warrants at $8.519 per warrant, raising approximately $21.5 million in gross proceeds for NextCure before fees. The warrants are exercisable at $0.001 per share and do not expire.
NextCure will not receive proceeds from any resale of the 2,523,477 shares, but would receive about $1,815 if all pre-funded warrants are exercised, which it expects to use for working capital and general corporate purposes. Shares outstanding were 5,203,299 as of November 25, 2025, assuming full warrant exercise. The company’s common stock trades on Nasdaq under the symbol “NXTC.”
NextCure, Inc. entered into a securities purchase agreement for a private placement of 708,428 shares of common stock at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares at $8.519 per warrant, raising gross proceeds of about $21.5 million before fees. The pre-funded warrants are exercisable immediately and do not expire. NextCure agreed to register the resale of the shares and warrant shares for the participating institutional and accredited investors and to temporarily restrict additional equity issuance, subject to exceptions. The company also announced that, based on its assumptions, its cash, cash equivalents and marketable securities are expected to fund planned operations into the first half of 2027.
NextCure, Inc. (NXTC) filed its Q3 2025 10‑Q reporting continued operating losses and a limited cash position, and raised substantial doubt about its ability to continue as a going concern. Cash, cash equivalents and marketable securities were $29.1 million as of September 30, 2025. Net loss was $8.6 million for the quarter and $46.4 million year‑to‑date, driven primarily by research and development.
R&D expense reflected the Zaiming license, with $17 million recorded as in‑process R&D in 2025. Operating cash outflow was $42.0 million for the nine months. Management expects additional losses and says current liquidity will not fund operations for one year after issuance, indicating the need for near‑term financing or partnerships.
Pipeline updates: SIM0505 (CDH6 ADC) first U.S. patient was dosed in October 2025, with proof‑of‑concept data expected in the first half of 2026. LNCB74 (B7‑H4 ADC) dosed its first patient in January 2025; a protocol amendment allowing higher dose escalation was cleared in November 2025. The company completed a 1‑for‑12 reverse stock split on July 14, 2025, and had 2,679,822 shares outstanding as of October 31, 2025.
NextCure, Inc. filed a current report stating that it released its financial results for the quarter ended September 30, 2025. On November 5, 2025, the company issued a press release with these quarterly results and attached it as Exhibit 99.1. The report clarifies that this press release is being furnished, not filed, which affects how it is treated under securities laws.
NextCure, Inc. (NXTC) Form 3/A reports that Simcere Zaiming, Inc. directly holds 338,636 shares of NextCure common stock. The amendment adds Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Hainan Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Limited, Ren Jinsheng and Tang Renhong as additional reporting persons to the original Form 3 filed by Simcere Zaiming, citing ownership chain and shared voting and investment power. The filing disclaims beneficial ownership except for pecuniary interest and states the amendment only adds reporting persons.